Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis

[1]  M. Nikiforova,et al.  Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. , 2005, The Journal of clinical investigation.

[2]  J. Mesirov,et al.  An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis , 2005, Nature Genetics.

[3]  S. Wiseman,et al.  TIMP1 and SERPIN‐A overexpression and TFF3 and CRABP1 underexpression as biomarkers for papillary thyroid carcinoma , 2004, Head & neck.

[4]  D. Sidransky,et al.  BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment , 2004, Modern Pathology.

[5]  V. Vasko,et al.  Chronic expression of RET/PTC 3 enhances basal and insulin‐stimulated PI3 kinase/AKT signaling and increases IRS‐2 expression in FRTL‐5 thyroid cells , 2004, Molecular carcinogenesis.

[6]  C. Lohse,et al.  Observer Variation in the Diagnosis of Follicular Variant of Papillary Thyroid Carcinoma , 2004, The American journal of surgical pathology.

[7]  M. Gariboldi,et al.  Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer , 2004, Oncogene.

[8]  S. Liyanarachchi,et al.  Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  C. Marshall,et al.  B-RAF is a therapeutic target in melanoma , 2004, Oncogene.

[10]  S. Hanash,et al.  Integrated global profiling of cancer , 2004, Nature Reviews Cancer.

[11]  F. Zunino,et al.  Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma. , 2004, Journal of the National Cancer Institute.

[12]  T. Fahey,et al.  0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(7):3214–3223 Printed in U.S.A. Copyright © 2004 by The Endocrine Society doi: 10.1210/jc.2003-031811 Molecular Profiling Distinguishes Papillary Carcinoma , 2022 .

[13]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[14]  H. Holzhausen,et al.  The tall-cell variant of papillary thyroid carcinoma: a multivariate analysis of clinical risk factors , 2004, Langenbeck's Archives of Surgery.

[15]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[16]  Markus Ringnér,et al.  Microarray expression profiling in melanoma reveals a BRAF mutation signature , 2004, Oncogene.

[17]  J. Dancey Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow. , 2004, Cancer cell.

[18]  Daniel Birnbaum,et al.  Identification and validation of an ERBB2 gene expression signature in breast cancers , 2004, Oncogene.

[19]  C. Sawyers Opportunities and challenges in the development of kinase inhibitor therapy for cancer. , 2003, Genes & development.

[20]  M. Nikiforova,et al.  BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. , 2003, The Journal of clinical endocrinology and metabolism.

[21]  R. Weber,et al.  c‐Met expression in tall cell variant papillary carcinoma of the thyroid , 2003, Cancer.

[22]  M. Pierotti,et al.  The Molecular Basis of Thyroid Epithelial Tumorigenesis , 2003, Tumori.

[23]  V. Trovisco,et al.  BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC , 2003, Oncogene.

[24]  A. Fischer,et al.  Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. , 2003, American journal of clinical pathology.

[25]  P. Ladenson,et al.  BRAF mutation in papillary thyroid carcinoma. , 2003, Journal of the National Cancer Institute.

[26]  M. Santoro,et al.  Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). , 2003, The Journal of clinical endocrinology and metabolism.

[27]  I. Shih,et al.  Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. , 2003, Journal of the National Cancer Institute.

[28]  J. Gray,et al.  The genetics and genomics of cancer , 2003, Nature Genetics.

[29]  B. Riedl,et al.  Design and discovery of small molecules targeting raf-1 kinase. , 2002, Current pharmaceutical design.

[30]  Charis Eng,et al.  Silencing of the PTEN tumor‐suppressor gene in anaplastic thyroid cancer , 2002, Genes, chromosomes & cancer.

[31]  David E. Misek,et al.  Gene-expression profiles predict survival of patients with lung adenocarcinoma , 2002, Nature Medicine.

[32]  Christos Sotiriou,et al.  Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. , 2002, Journal of the National Cancer Institute.

[33]  J. Fagin Perspective: Lessons Learned from Molecular Genetic Studies of Thyroid Cancer-Insights into Pathogenesis and Tumor-Specific Therapeutic Targets. , 2002, Endocrinology.

[34]  M. Nikiforova,et al.  Prevalence of RET/PTC Rearrangements in Hashimoto's Thyroiditis and Papillary Thyroid Carcinomas , 2002, International journal of surgical pathology.

[35]  C Eng,et al.  Gene expression in papillary thyroid carcinoma reveals highly consistent profiles , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[36]  E. Pravatà,et al.  Reply , 2001, British Journal of Cancer.

[37]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[38]  G. Bollag,et al.  Discovery of a novel Raf kinase inhibitor. , 2001, Endocrine-related cancer.

[39]  A. Stoppacciaro,et al.  Met protein and hepatocyte growth factor (HGF) in papillary carcinoma of the thyroid: evidence for a pathogenetic role in tumourigenesis , 2001, The Journal of pathology.

[40]  E. Dougherty,et al.  Gene-expression profiles in hereditary breast cancer. , 2001, The New England journal of medicine.

[41]  F. Moretti,et al.  Molecular pathogenesis of thyroid nodules and cancer. , 2000, Bailliere's best practice & research. Clinical endocrinology & metabolism.

[42]  M. Ringel,et al.  Tall Cell Variant: An Aggressive Form of Papillary Thyroid Carcinoma , 2000, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[43]  I. Fleming,et al.  A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985‐1995 , 1998, Cancer.

[44]  A. Bounacer,et al.  High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation , 1997, Oncogene.

[45]  N. Farid,et al.  Immune response to papillary thyroid carcinoma. , 1996, The Journal of clinical endocrinology and metabolism.

[46]  S. Asa,et al.  Prevalence of activating ras mutations in morphologically characterized thyroid nodules. , 1996, Thyroid : official journal of the American Thyroid Association.

[47]  K. Umeki,et al.  IMMUNOHISTOCHEMICAL LOSS OF THYROID PEROXIDASE IN PAPILLARY THYROID CARCINOMA: STRONG SUPPRESSION OF PEROXIDASE GENE EXPRESSION , 1996, The Journal of pathology.

[48]  A. de Leiva,et al.  Ras Oncogene Mutations in Thyroid Tumors: Polymerase Chain Reaction‐Restriction‐Fragment‐Length Polymorphism Analysis from Paraffin‐Embedded Tissues , 1996, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[49]  J. Baker The immune response to papillary thyroid cancer. , 1995, The Journal of clinical endocrinology and metabolism.

[50]  T. Oyama,et al.  Stepwise participation of p53 gene mutation during dedifferentiation of human thyroid carcinomas. , 1994, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[51]  S. Jhiang,et al.  Thyroid peroxidase expression and DNA polymorphisms in thyroid cancer. , 1994, Biochemical and biophysical research communications.

[52]  M. Pierotti,et al.  Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. , 1993, The Journal of clinical investigation.

[53]  I D Hay,et al.  Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. , 1992, The Journal of clinical investigation.

[54]  A. Thor,et al.  Ras oncogene mutations in benign and malignant thyroid neoplasms. , 1991, The Journal of clinical endocrinology and metabolism.

[55]  S. Rubin,et al.  Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. , 1990, Molecular endocrinology.

[56]  E. Kaplan,et al.  Natural history, treatment, and course of papillary thyroid carcinoma. , 1990, The Journal of clinical endocrinology and metabolism.

[57]  M. Stone Asymptotics for and against cross-validation , 1977 .